Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases.
Excellent balance sheet with moderate growth potential.
Share Price & News
How has Enanta Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ENTA's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ENTA underperformed the US Biotechs industry which returned 0% over the past year.
Return vs Market: ENTA underperformed the US Market which returned -11.5% over the past year.
Price Volatility Vs. Market
How volatile is Enanta Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StShould You Be Tempted To Sell Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Because Of Its P/E Ratio?
4 weeks ago | Simply Wall StDoes Enanta Pharmaceuticals's (NASDAQ:ENTA) Share Price Gain of 76% Match Its Business Performance?
1 month ago | Simply Wall StShould You Worry About Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Salary Level?
Is Enanta Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ENTA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ENTA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ENTA is poor value based on its PE Ratio (27.4x) compared to the Biotechs industry average (15.4x).
PE vs Market: ENTA is poor value based on its PE Ratio (27.4x) compared to the US market (13x).
Price to Earnings Growth Ratio
PEG Ratio: ENTA is poor value based on its PEG Ratio (1.4x)
Price to Book Ratio
PB vs Industry: ENTA is good value based on its PB Ratio (1.9x) compared to the US Biotechs industry average (2.5x).
How is Enanta Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ENTA's forecast earnings growth (18.9% per year) is above the savings rate (1.7%).
Earnings vs Market: ENTA's earnings (18.9% per year) are forecast to grow faster than the US market (12.3% per year).
High Growth Earnings: ENTA's earnings are forecast to grow, but not significantly.
Revenue vs Market: ENTA's revenue (14% per year) is forecast to grow faster than the US market (7.3% per year).
High Growth Revenue: ENTA's revenue (14% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ENTA's Return on Equity is forecast to be high in 3 years time
How has Enanta Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ENTA has high quality earnings.
Growing Profit Margin: ENTA's current net profit margins (18%) are lower than last year (36.2%).
Past Earnings Growth Analysis
Earnings Trend: ENTA's earnings have declined by -3.9% per year over the past 5 years.
Accelerating Growth: ENTA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ENTA had negative earnings growth (-60.8%) over the past year, making it difficult to compare to the Biotechs industry average (22%).
Return on Equity
High ROE: ENTA's Return on Equity (7%) is considered low.
How is Enanta Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: ENTA's short term assets ($440.5M) exceed its short term liabilities ($19.1M).
Long Term Liabilities: ENTA's short term assets ($440.5M) exceed its long term liabilities ($9.5M).
Debt to Equity History and Analysis
Debt Level: ENTA's debt to equity ratio (0.3%) is considered satisfactory.
Reducing Debt: ENTA's debt to equity ratio has increased from 0.09% to 0.3% over the past 5 years.
Debt Coverage: ENTA's debt is well covered by operating cash flow (3287.9%).
Interest Coverage: ENTA earns more interest than it pays, so coverage of interest payments is not a concern.
Inventory Level: ENTA has a low level of unsold assets or inventory.
Debt Coverage by Assets: ENTA's debt is covered by short term assets (assets are 270.6x debt).
What is Enanta Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ENTA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ENTA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ENTA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ENTA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ENTA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jay Luly (63yo)
Dr. Jay R. Luly, Ph.D. has been the Chief Executive Officer and President of Enanta Pharmaceuticals, Inc. since July 2003. Dr. Luly joined Enanta in July 2003. Previously he was employed at Oxford Bioscien ...
CEO Compensation Analysis
Compensation vs Market: Jay's total compensation ($USD4.48M) is above average for companies of similar size in the US market ($USD3.12M).
Compensation vs Earnings: Jay's compensation has been consistent with company performance over the past year.
|Senior VP of Finance & Administration and CFO||16.5yrs||US$1.53m||0.21% $1.9m|
|Senior VP of Research & Development and Chief Scientific Officer||20.33yrs||US$1.63m||1.54% $14.4m|
|Senior VP||5.83yrs||US$1.49m||0.22% $2.1m|
|Senior VP & Chief Medical Officer||4.75yrs||US$1.61m||0.078% $735.3k|
|Director of Investor Relations||no data||no data||no data|
Experienced Management: ENTA's management team is seasoned and experienced (16.5 years average tenure).
|Independent Non-Executive Chairman||4.25yrs||US$351.58k||no data|
|Independent Director||8.75yrs||US$332.00k||0.077% $719.4k|
|Independent Director||2.5yrs||US$317.00k||no data|
|Independent Director||6yrs||US$324.50k||no data|
|Independent Director||3.33yrs||US$319.50k||no data|
Experienced Board: ENTA's board of directors are considered experienced (5.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Enanta Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Enanta Pharmaceuticals, Inc.
- Ticker: ENTA
- Exchange: NasdaqGS
- Founded: 1995
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$937.046m
- Shares outstanding: 19.92m
- Website: https://www.enanta.com
Number of Employees
- Enanta Pharmaceuticals, Inc.
- 500 Arsenal Street
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ENTA||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Mar 2013|
|9EP||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Mar 2013|
|9EP||BRSE (Berne Stock Exchange)||Yes||Common Stock||CH||CHF||Mar 2013|
Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/29 04:23|
|End of Day Share Price||2020/03/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.